Literature DB >> 26183986

Private and public coverage policies for rituximab in the treatment of immunobullous disease in the United States.

Romi Bloom1, Kyle T Amber2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26183986     DOI： 10.1016/j.jaad.2015.04.040

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  1 in total

Review 1.  Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers.

Authors:  Manuel Valdebran; Kyle T Amber
Journal:  JAMA Dermatol       Date:  2017-11-01       Impact factor: 10.282
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.